SANOVO trial demonstrated significant PFS benefit

Summary by AI BETAClose X

HUTCHMED announced positive high-level results from the SANOVO China Phase III trial, demonstrating that ORPATHYS® plus TAGRISSO® significantly improved progression-free survival in treatment-naïve patients with MET-overexpressing, EGFR-mutated non-small cell lung cancer compared to TAGRISSO® alone. The combination also showed encouraging overall survival benefits, building on previous trial successes and supporting its potential as a first-line treatment strategy. The safety profile of the combination was consistent with known profiles, with no new safety concerns identified.

Disclaimer*

UK 100

Latest directors dealings